<DOC>
	<DOCNO>NCT00003064</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy autologous peripheral stem cell transplantation treat patient recurrent persistent epithelial ovarian cancer , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Recurrent Persistent Epithelial Ovarian Cancer , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose topotecan fix dose etoposide phosphate component multicourse high dose chemotherapy regimen support peripheral blood stem cell transplantation patient persistent recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer . - Evaluate response , time progression , disease free survival , overall survival patient population . OUTLINE : This dose escalation study topotecan . All patient receive induction therapy consist 1 2 course mobilization therapy . Subcutaneous filgrastim ( G-CSF ) give begin 24 hour induction dose . Following induction therapy , peripheral blood stem cell ( PBSC ) harvest . After patient receive high dose paclitaxel carboplatin chemotherapy , portion PBSC reinfused . When patient recover paclitaxel/carboplatin chemotherapy administration topotecan etoposide phosphate begin . Topotecan administer , 72 hour continuous infusion , accord dose escalation schedule fix dose etoposide phosphate . A second portion PBSC reinfused topotecan/etoposide phosphate chemotherapy . A course thiotepa give along final portion PBSC treatment topotecan etoposide phosphate . Dose escalation topotecan continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 patient experience dose limit toxicity . Patients follow every 3 month 1 year every 4 month thereafter determine progression free overall survival . PROJECTED ACCRUAL : Approximately 25-30 patient accrued phase I portion study , 25 patient accrue phase II portion .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven persistent recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer follow least 3 course initial standard platinum base chemotherapy OR radiologic evidence recurrence CA125 great 100 Initial stage IV disease complete response follow platinum base therapy allow No brain metastases Not eligible high priority national institutional study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Greater 2 month Hematopoietic : WBC great 3000/mm3 Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 time normal SGOT SGPT less 1.5 time normal PT/PTT within normal limit Renal : BUN le 1.5 time normal Creatinine le 1.5 time normal Creatinine clearance great 55 mL/min Cardiovascular : LVEF least 45 % Other : Not pregnant nursing HIV negative No prior malignancy curatively treat carcinoma situ cervix , nonmelanoma skin cancer , breast cancer risk recurrence sufficiently low No serious illness would prevent treatment PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Other : No concurrent acetaminophen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>